Gonadotropin-releasing hormone agonists
Gonadotropin-releasing hormone agonists has been studied in 12 papers since 2016: 2 observational studies in people, 1 in animals, 9 reviews; 4 in the past year. The newest paper, Nov 16, 2026: “Hormonal Therapy for Osteoporosis: Mechanisms, Trial Evidence, and Current Place in Fracture Prevention”.
12 papers study it10 findingsUpdated
2 new papers in 30 daysSee all 12 papers on gonadotropin-releasing hormone agonists
At a glance
The findings reach people, from one lab or study. 3 independent labs in 3 countries.
“with the largest increases observed among those receiving regimens including gonadotropin-releasing hormone agonists.”
None of its findings points the other way.
- 3 independent labs in 3 countries
- Funders: Korea National Institute of Health and 5 more
- Humans2
- Animals1
What did studies of gonadotropin-releasing hormone agonists find?
4Studies of gonadotropin-releasing hormone agonists measured 4 outcomes, among them serious adverse events, BMD Z-score and premature ovarian failure.
Serious adverse events
no changein humans1RR 0.99
1 study
Serious adverse events
no changein humans1RR 0.99
Gonadotropin-releasing hormone agonists showed no clear effect on serious adverse events in humans during cyclophosphamide therapy (RR 0.99, 95% CI 0.50-1.93).
“The incidence of serious adverse events was similar between groups (10 of 36 versus 10 of 34 women; risk ratio: 0.99; 95% CI: 0.50-1.93).”
Reviewduring cyclophosphamide therapyfemales
Reproduction & fertility
BMD Z-score
downin humans1
1 study
BMD Z-score
downin humans1
Gonadotropin-releasing hormone agonists decrease BMD Z-score in humans during hormonal suppression.
“In adolescents, GnRH-agonists predictably reduce BMD Z-scores during hormonal suppression”
Reviewduring hormonal suppression
Bone health in gender-diverse individuals: current challenges and future directions
Hormones (Athens, Greece)
Premature ovarian failure
no changein humans1
1 study
Premature ovarian failure
no changein humans1
Gonadotropin-releasing hormone agonists were not clearly linked with premature ovarian failure in humans Following myeloablative hematopoietic cell transplantation.
“it cannot reduce the incidence of premature ovarian failure in women of reproductive age following myeloablative HSCT.”
HumansFollowing myeloablative hematopoietic cell transplantationOvary3.75 mg per course; at least 2 coursesfemalesn = 234
Scientific reports
Visible ovarian follicles
no changein humans1
1 study
Visible ovarian follicles
no changein humans1
Gonadotropin-releasing hormone agonists were not clearly linked with visible ovarian follicles in humans (Myeloablative hematopoietic cell transplantation) (16.88% vs. 13.38%, P = 0.474).
“There was no difference in visible follicles by follow-up ultrasound in the two groups after HSCT (16.88% vs. 13.38%, P = 0.474).”
HumansMyeloablative hematopoietic cell transplantationOvary3.75 mg per course; at least 2 coursesAfter transplantationfemalesn = 234
Scientific reports
What is gonadotropin-releasing hormone agonists linked with?
6Studies link gonadotropin-releasing hormone agonists with 6 measures, among them menopausal symptoms, primary ovarian insufficiency and follicle stimulating hormone.
Menopausal symptoms
upin humans1
1 study
Menopausal symptoms
upin humans1
Gonadotropin-releasing hormone agonists are associated with menopausal symptoms in humans (Premenopausal women within the breast cancer cohort).
“with the largest increases observed among those receiving regimens including gonadotropin-releasing hormone agonists.”
HumansPremenopausal women within the breast cancer cohortregimens including gonadotropin-releasing hormone agonists3 yearsfemales
Breast (Edinburgh, Scotland)
Primary ovarian insufficiency
downin humans1RR 0.16
1 study
Primary ovarian insufficiency
downin humans1RR 0.16
Gonadotropin-releasing hormone agonists lower the risk of primary ovarian insufficiency in humans during cyclophosphamide therapy (RR 0.16, 95% CI 0.07-0.37).
“Premature ovarian insufficiency occurred in 5 of 93 women receiving gonadotropin-releasing hormone agonists and in 28 of 69 controls, corresponding to a risk ratio of 0.16 (95% confidence interval (CI): 0.07-0.37).”
Reviewduring cyclophosphamide therapyfemalesn = 162
Reproduction & fertility
Follicle stimulating hormone
downin humans1
1 study
Follicle stimulating hormone
downin humans1
Gonadotropin-releasing hormone agonists are associated with follicle stimulating hormone in humans (Myeloablative hematopoietic cell transplantation) (98.00 mIU/ml vs. 117.53 mIU/ml, P = 0.001).
“The level of FSH at 6-12 months after transplantation was lower (98.00 mIU/ml vs. 117.53 mIU/ml, P = 0.001).”
HumansMyeloablative hematopoietic cell transplantation3.75 mg per course; at least 2 courses6–12 months after transplantationfemalesn = 234
Scientific reports
Menopause-related symptoms
downin humans1
1 study
Menopause-related symptoms
downin humans1
Gonadotropin-releasing hormone agonists are associated with menopause-related symptoms in humans (Myeloablative hematopoietic cell transplantation) (46.75% vs. 19.75%, P < 0.001).
“The menopausal symptoms of the patients in the treatment group were reduced after transplantation (46.75% vs. 19.75%, P < 0.001).”
HumansMyeloablative hematopoietic cell transplantation3.75 mg per course; at least 2 coursesAfter transplantationfemalesn = 234
Scientific reports
Vaginal bleeding
downin humans1
1 study
Vaginal bleeding
downin humans1
Gonadotropin-releasing hormone agonists are associated with vaginal bleeding In the laminar air-flow room during myeloablative hematopoietic cell transplantation (24.68% vs. 79.62%, P < 0.001).
“The incidence of vaginal bleeding in the LAFR in the treatment group was significantly lower than that in the control group”
HumansIn the laminar air-flow room during myeloablative hematopoietic cell transplantation3.75 mg per course; at least 2 coursesfemalesn = 234
Scientific reports
Gonadotoxicity
downin humans1
1 study
Gonadotoxicity
downin humans1
Gonadotropin-releasing hormone agonists lower the risk of gonadotoxicity in humans (receiving chemotherapy).
“Ovarian suppression with gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is now recommended as an option to reduce the risk of gonadotoxicity”
Reviewreceiving chemotherapyovaryduring chemotherapyfemales
How to Protect Ovarian Function before and during Chemotherapy?
Journal of clinical medicine
Latest
4 papers in 12 monthsHormonal Therapy for Osteoporosis: Mechanisms, Trial Evidence, and Current Place in Fracture Prevention
Gonadotropin-releasing hormone agonists during cyclophosphamide for ovarian protection in systemic lupus erythematosus
Kuntai capsule for the treatment of menopausal symptoms induced by GnRH-a therapy: A systematic review and meta-analysis of randomized controlled trials
Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation
How to Protect Ovarian Function before and during Chemotherapy?
See all 12 papers on gonadotropin-releasing hormone agonists